In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium

Mycoplasma genitalium has developed resistance to first-line azithromycin and second-line moxifloxacin. Third-line pristinamycin is only 75% effective. Gepotidacin, a novel triazaacenaphthylene topoisomerase II inhibitor, blocks bacterial DNA replication. We determined the in vitro activity of gepot...

Descripción completa

Detalles Bibliográficos
Autores principales: Jensen, Jørgen Skov, Nørgaard, Christina, Scangarella-Oman, Nicole, Unemo, Magnus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473033/
https://www.ncbi.nlm.nih.gov/pubmed/32552547
http://dx.doi.org/10.1080/22221751.2020.1775498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7473033/
https://www.ncbi.nlm.nih.gov/pubmed/32552547
http://dx.doi.org/10.1080/22221751.2020.1775498

Ejemplares similares